NCT04795427 - Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

May 29, 2023

Study Completion Date

November 18, 2024

Conditions

Leukemia, Chronic Myelogenous

Interventions

DRUG

asciminib

Asciminib comes in 20 mg and 40 mg tablets and is taken orally twice daily

OTHER

best available treatment

Best available treatment will be based on investigator's choice identified prior to randomization. Dose and frequency will depend on label and institutional guidelines for various BAT

Trial Locations (20)

100044

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

110004

Novartis Investigative Site, Shenyang

130021

Novartis Investigative Site, Changchun

200025

Novartis Investigative Site, Shanghai

210000

Novartis Investigative Site, Nanjing

215004

Novartis Investigative Site, Suzhou

226000

Novartis Investigative Site, Nantong

300020

Novartis Investigative Site, Tianjin

310003

Novartis Investigative Site, Hangzhou

325000

Novartis Investigative Site, Wenzhou

330006

Novartis Investigative Site, Nanchang

400010

Novartis Investigative Site, Chongqing

430022

Novartis Investigative Site, Wuhan

450008

Novartis Investigative Site, Zhengzhou

450052

Novartis Investigative Site, Zhengzhou

510515

Novartis Investigative Site, Guangzhou

518037

Novartis Investigative Site, Shenzhen

610041

Novartis Investigative Site, Chengdu

710004

Novartis Investigative Site, Xian